Figure 5.
(A) Proportion of patients with Grade 2+ or Grade 3+ mucositis during treatment (week 1-9) and follow-up (weeks 11-14) using NCI-CTCAE 3.0. (B) Proportion of patients with Grade 2+ or Grade 3+ Dermatitis during treatment (weeks 1-9) and follow up (weeks 11-14).